Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1997 1
1998 3
2001 1
2002 3
2004 4
2005 3
2007 7
2008 31
2009 31
2010 81
2011 78
2012 97
2013 123
2014 125
2015 156
2016 180
2017 257
2018 244
2019 257
2020 346
2021 469
2022 456
2023 455
2024 374
2025 1

Text availability

Article attribute

Article type

Publication date

Search Results

3,414 results

Results by year

Filters applied: . Clear all
Page 1
Pathogenesis of Triple-Negative Breast Cancer.
Derakhshan F, Reis-Filho JS. Derakhshan F, et al. Annu Rev Pathol. 2022 Jan 24;17:181-204. doi: 10.1146/annurev-pathol-042420-093238. Annu Rev Pathol. 2022. PMID: 35073169 Free PMC article. Review.
Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of fundamentally different diseases with different histologic, genomic, and immunologic profiles, which are aggregated under this term because of their lack of estrogen receptor, pr …
Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of fundamentally different diseases with …
Epidemiology of Triple-Negative Breast Cancer: A Review.
Howard FM, Olopade OI. Howard FM, et al. Cancer J. 2021 Jan-Feb 01;27(1):8-16. doi: 10.1097/PPO.0000000000000500. Cancer J. 2021. PMID: 33475288 Review.
Triple-negative breast cancer accounted for 12% of breast cancers diagnosed in the United States from 2012 to 2016, with a 5-year survival 8% to 16% lower than hormone receptor-positive disease. However, preventive and screening strategies remai …
Triple-negative breast cancer accounted for 12% of breast cancers diagnosed in the United States from 201 …
Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L, Duan JJ, Bian XW, Yu SC. Yin L, et al. Breast Cancer Res. 2020 Jun 9;22(1):61. doi: 10.1186/s13058-020-01296-5. Breast Cancer Res. 2020. PMID: 32517735 Free PMC article. Review.
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include hi …
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express es …
Recent advances in therapeutic strategies for triple-negative breast cancer.
Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y. Li Y, et al. J Hematol Oncol. 2022 Aug 29;15(1):121. doi: 10.1186/s13045-022-01341-0. J Hematol Oncol. 2022. PMID: 36038913 Free PMC article. Review.
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. ...In addition, immunotherapy has also been demonstrated to improve overall survival and response in TNBC. In this review …
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a po …
Advances in systemic therapies for triple negative breast cancer.
Leon-Ferre RA, Goetz MP. Leon-Ferre RA, et al. BMJ. 2023 May 30;381:e071674. doi: 10.1136/bmj-2022-071674. BMJ. 2023. PMID: 37253507 Review.
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the highest rates of recurrence and mortality. ...Furthermore, advances in drug development have led to the approval of antibody-drug conjugates that a …
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the highest …
Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE, Tolaney SM. Keenan TE, et al. J Natl Compr Canc Netw. 2020 Apr;18(4):479-489. doi: 10.6004/jnccn.2020.7554. J Natl Compr Canc Netw. 2020. PMID: 32259782 Review.
However, the single-agent efficacy of ICIs in breast cancer is low, including in triple-negative breast cancer (TNBC), which has several key characteristics that enhance ICI responses. Strategies to improve anticancer immune responses in …
However, the single-agent efficacy of ICIs in breast cancer is low, including in triple-negative breast …
Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review.
van den Ende NS, Nguyen AH, Jager A, Kok M, Debets R, van Deurzen CHM. van den Ende NS, et al. Int J Mol Sci. 2023 Feb 3;24(3):2969. doi: 10.3390/ijms24032969. Int J Mol Sci. 2023. PMID: 36769287 Free PMC article. Review.
Around 40-50% of all triple-negative breast cancer (TNBC) patients achieve a pathological complete response (pCR) after treatment with neoadjuvant chemotherapy (NAC). ...Overall, the most frequently reported biomarkers associated with a pCR were a high …
Around 40-50% of all triple-negative breast cancer (TNBC) patients achieve a pathological complete response (pCR …
Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.
Bianchini G, De Angelis C, Licata L, Gianni L. Bianchini G, et al. Nat Rev Clin Oncol. 2022 Feb;19(2):91-113. doi: 10.1038/s41571-021-00565-2. Epub 2021 Nov 9. Nat Rev Clin Oncol. 2022. PMID: 34754128 Review.
Tumour heterogeneity and a long-standing paucity of effective therapies other than chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype with the least favourable outcomes. In the past few years, advances in omics tech …
Tumour heterogeneity and a long-standing paucity of effective therapies other than chemotherapy have contributed to triple-negativ …
Advances in immunotherapy for triple-negative breast cancer.
Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J, Zhang Z, Qiu P, Gu X. Liu Y, et al. Mol Cancer. 2023 Sep 2;22(1):145. doi: 10.1186/s12943-023-01850-7. Mol Cancer. 2023. PMID: 37660039 Free PMC article. Review.
This offers the possibility of reducing mortality in triple-negative breast cancer (TNBC). MAIN BODY: Immunotherapy approaches for TNBC have been diversified in recent years, with breakthroughs in the treatment of this entity. Research on immune checkp …
This offers the possibility of reducing mortality in triple-negative breast cancer (TNBC). MAIN BODY: Immunother …
Triple-negative breast cancer: promising prognostic biomarkers currently in development.
Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Sukumar J, et al. Expert Rev Anticancer Ther. 2021 Feb;21(2):135-148. doi: 10.1080/14737140.2021.1840984. Expert Rev Anticancer Ther. 2021. PMID: 33198517 Free PMC article. Review.
Introduction: Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer associated with poor prognosis and limited treatment options. ...Biomarkers reviewed include epidermal growth factor receptor (EGFR), vascular endot …
Introduction: Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer associat …
3,414 results